YOUR BUSINESS AUTHORITY
Springfield, MO
Celgene Corp. signed on to purchase blood-disease biotechnology company Impact Biomedicines.
The deal is worth as much as $7 billion, subject to milestones related to regulatory obstacles and sales performance.
Celgene agreed to make a $1.1 billion upfront payment for the San Diego-based privately held company.
Read more from The Wall Street Journal.
Nixa Superintendent Gearl Loden weighs in on A-F grade cards.
SBJ announces executive newsroom hires
Thanksgiving staple recalled at Costco
HBA of Greater Springfield executive officer to retire
Timeshare exit company owner sentenced for tax evasion
Warren Buffett donates $5.5B worth of Berkshire Hathaway shares
Letter to the Editor: No half-baked cake for our kids. No half-baked school grades, either.